- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01452763
Efficacy and Safety of TAK-438 for the Prevention of Recurrent Gastric or Duodenal Ulcers During Therapy of Low-dose Aspirin
January 17, 2014 updated by: Takeda
A Phase 3, Multicenter, Randomized, Double-blind, AG-1749-controlled, Parallel-group, Comparison Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg, Orally, Once Daily) for the Prevention of Recurrent Gastric or Duodenal Ulcers During Long-term Therapy of Low-dose Aspirin
The purpose of this study is to evaluate the efficacy of TAK-438, once daily (QD) compared to AG-1749 (Lansoprazole) in patients with a history of gastric or duodenal ulcer who require long-term therapy of low-dose aspirin.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
621
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Aichi
-
Komaki-shi, Aichi, Japan
-
Seto-shi, Aichi, Japan
-
-
Akita
-
Akita-shi, Akita, Japan
-
-
Chiba
-
Ichikawa-shi, Chiba, Japan
-
Kisarazu-shi, Chiba, Japan
-
Matsudo-shi, Chiba, Japan
-
-
Ehime
-
Imabari-shi, Ehime, Japan
-
Matsuyama-shi, Ehime, Japan
-
Niihama-shi, Ehime, Japan
-
-
Fukui
-
Fukui-shi, Fukui, Japan
-
-
Fukuoka
-
Chikushino-shi, Fukuoka, Japan
-
Fukuoka-shi, Fukuoka, Japan
-
Kasuya-gun, Fukuoka, Japan
-
Kitakyushu-shi, Fukuoka, Japan
-
Miyako-gun, Fukuoka, Japan
-
Onga-gun, Fukuoka, Japan
-
Yanagawa-shi, Fukuoka, Japan
-
Yukuhashi-shi, Fukuoka, Japan
-
-
Fukushima
-
Koriyama-shi, Fukushima, Japan
-
-
Gifu
-
Gifu-shi, Gifu, Japan
-
-
Gunma
-
Takasaki-shi, Gunma, Japan
-
-
Hiroshima
-
Fukuyama-shi, Hiroshima, Japan
-
Hatsukaichi-shi, Hiroshima, Japan
-
Hiroshima-shi, Hiroshima, Japan
-
-
Hokkaido
-
Asahikawa-shi, Hokkaido, Japan
-
Obihiro-shi, Hokkaido, Japan
-
Sapporo-shi, Hokkaido, Japan
-
Tomakomaki-shi, Hokkaido, Japan
-
-
Hyougo
-
Kobe-shi, Hyougo, Japan
-
Nishinomiya-shi, Hyougo, Japan
-
Takarazuka-shi, Hyougo, Japan
-
-
Ibaragi
-
Koga-shi, Ibaragi, Japan
-
Tsuchiura-shi, Ibaragi, Japan
-
-
Ishikawa
-
Kanazawa-shi, Ishikawa, Japan
-
Komatsu-shi, Ishikawa, Japan
-
Nomi-shi, Ishikawa, Japan
-
Shiroyama-shi, Ishikawa, Japan
-
-
Kagawa
-
Takamatsu-shi, Kagawa, Japan
-
-
Kagoshima
-
Ibusuki-shi, Kagoshima, Japan
-
Ichikikushikino-shi, Kagoshima, Japan
-
Izumi-shi, Kagoshima, Japan
-
-
Kanagawa
-
Atsugi-shi, Kanagawa, Japan
-
Kawasaki-shi, Kanagawa, Japan
-
Sagamihara-shi, Kanagawa, Japan
-
Yokohama-shi, Kanagawa, Japan
-
-
Kochi
-
Kochi-shi, Kochi, Japan
-
-
Kumamoto
-
Kumamoto-shi, Kumamoto, Japan
-
-
Kyoto
-
Kyoto-shi, Kyoto, Japan
-
Uji-shi, Kyoto, Japan
-
-
Mie
-
Tsu-shi, Mie, Japan
-
-
Miyagi
-
Sendai-shi, Miyagi, Japan
-
-
Nagasaki
-
Nagasaki-shi, Nagasaki, Japan
-
-
Nara
-
Nara-shi, Nara, Japan
-
-
Niigata
-
Niigata-shi, Niigata, Japan
-
-
Oita
-
Oita-shi, Oita, Japan
-
-
Osaka
-
Osaka-shi, Osaka, Japan
-
Sakai-shi, Osaka, Japan
-
Tondabayashi-shi, Osaka, Japan
-
-
Saitama
-
Ageo-shi, Saitama, Japan
-
Hiki-gun, Saitama, Japan
-
Kumagaya-shi, Saitama, Japan
-
Saitama-shi, Saitama, Japan
-
Sayama-shi, Saitama, Japan
-
Tokorozawa-shi, Saitama, Japan
-
-
Shiga
-
Otsu-shi, Shiga, Japan
-
-
Tochigi
-
Utsunomiya-shi, Tochigi, Japan
-
-
Tokyo
-
Adachi-ku, Tokyo, Japan
-
Hachioji-shi, Tokyo, Japan
-
Koto-ku, Tokyo, Japan
-
Meguro-ku, Tokyo, Japan
-
Minato-ku, Tokyo, Japan
-
Shinjuku-ku, Tokyo, Japan
-
-
Toyama
-
Tonami-shi, Toyama, Japan
-
Toyama-shi, Toyama, Japan
-
-
Yamaguchi
-
Iwakuni-shi, Yamaguchi, Japan
-
Shimonoseki-shi, Yamaguchi, Japan
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Participants who require continuous low-dose aspirin therapy during the treatment period with the study drug
- Participants who have a history of ulcer in stomach or duodenum, endoscopically confirmed
- Outpatient (including inpatient for examinations)
Exclusion Criteria:
- Participants scheduled to change the type and dosage regimen of low-dose aspirin
- Participants with ulcers or bleeding in stomach or duodenum, endoscopically confirmed
- Participants with small intestine bleeding, large intestine bleeding, or gastrointestinal bleeding of unknown etiology
- Participants who have a history of surgery which affects gastric acid secretion (e.g., resection of upper gastrointestinal tract, vagotomy) or who are scheduled to undergo such surgery
- Participants with a previous or current history of Zollinger-Ellison syndrome, or other gastric acid hypersecretion disorders
- Participants with a previous or current history of aspirin-induced asthma
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: TAK-438 10 mg QD
|
TAK-438 10 mg tablets, orally, once daily for up to 24 weeks.
Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
TAK-438 20 mg tablets, orally, once daily for up to 24 weeks.
TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
|
Experimental: TAK-438 20 mg QD
|
TAK-438 10 mg tablets, orally, once daily for up to 24 weeks.
Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
TAK-438 20 mg tablets, orally, once daily for up to 24 weeks.
TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
|
Active Comparator: Lansoprazole 15 mg QD
|
Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
Lansoprazole 15 mg capsules, orally, once daily for up to 24 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence rate of gastric or duodenal ulcer within 24 weeks
Time Frame: 24 weeks
|
Mucosal defects with a white coating of 3 mm or larger will be determined as ulcers.
Recurrence rate of gastric or duodenal ulcer within 24 weeks will be calculated for each treatment group.
|
24 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Recurrence rate of gastric or duodenal ulcer within 12 weeks
Time Frame: 12 weeks
|
12 weeks
|
Gastric mucosal injury
Time Frame: 24 Weeks
|
24 Weeks
|
Duodenal mucosal injury
Time Frame: 24 weeks
|
24 weeks
|
Occurrence rate of hemorrhagic lesion in stomach or duodenum
Time Frame: 24 weeks
|
24 weeks
|
Time to recurrence of gastric or duodenal ulcer
Time Frame: 24 weeks
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2011
Primary Completion (Actual)
April 1, 2013
Study Completion (Actual)
April 1, 2013
Study Registration Dates
First Submitted
September 16, 2011
First Submitted That Met QC Criteria
October 14, 2011
First Posted (Estimate)
October 17, 2011
Study Record Updates
Last Update Posted (Estimate)
January 20, 2014
Last Update Submitted That Met QC Criteria
January 17, 2014
Last Verified
January 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Pathologic Processes
- Gastrointestinal Diseases
- Stomach Diseases
- Intestinal Diseases
- Peptic Ulcer
- Duodenal Diseases
- Ulcer
- Stomach Ulcer
- Duodenal Ulcer
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Gastrointestinal Agents
- Anti-Ulcer Agents
- Proton Pump Inhibitors
- Dexlansoprazole
- Lansoprazole
Other Study ID Numbers
- TAK-438/CCT-302
- U1111-1123-8746 (Registry Identifier: WHO (UTN))
- JapicCTI-111610 (Registry Identifier: JapicCTI)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gastric Ulcers
-
TakedaCompletedGastric Ulcers | Duodenal UlcersJapan
-
TakedaCompleted
-
TakedaCompletedGastric Ulcers | Duodenal UlcersJapan
-
Eisai Co., Ltd.CompletedGastric Ulcers Duodenal Ulcers Caused by Low-dose AspirinJapan
-
AstraZenecaCompleted
-
POZENCompletedAspirin-Associated Gastric UlcersUnited States
-
Boryung Pharmaceutical Co., LtdCompleted
Clinical Trials on TAK-438
-
TakedaCompletedJapanese Healthy Adult MaleJapan
-
TakedaCompleted
-
TakedaCompletedGastroesophageal Reflux Disease (GERD) | Erosive Esophagitis(EE)United Kingdom
-
TakedaCompleted
-
TakedaCompletedErosive EsophagitisJapan
-
TakedaCompletedAscending Single Dose Study
-
TakedaCompletedNon-erosive Gastroesophageal Reflux DiseaseJapan
-
TakedaCompletedNon-erosive Gastroesophageal Reflux DiseaseJapan
-
TakedaCompletedGastric Ulcer, Duodenal Ulcer, and Reflux EsophagitisJapan
-
TakedaCompleted